This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.

Inclusion Criteria:

• Adult patients, >/= 18 years of age at diagnosis
• Histologically confirmed new diagnosis of unresectable or metastatic melanoma
• Patients with tumor samples available for assessment of BRAF V600 mutation

Exclusion Criteria:

• Prior systemic therapy for metastatic disease
• Participation in interventional clinical trials

Patients with newly diagnosed unresectable or metastatic melanoma